- 全部删除
您的购物车当前为空
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。


为众多的药物研发团队赋能,
让新药发现更简单!
AGI-14100 是一种新型且可口服的 mIDH1 抑制剂。AGI-14100 用于治疗原发性人类髓性白血病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 987 | In stock | |
| 5 mg | ¥ 2,350 | In stock | |
| 10 mg | ¥ 3,260 | In stock | |
| 25 mg | ¥ 4,700 | In stock | |
| 50 mg | ¥ 6,380 | In stock | |
| 100 mg | ¥ 8,590 | In stock | |
| 200 mg | ¥ 11,600 | In stock |
AGI-14100 相关产品
| 产品描述 | AGI-14100 is a novel and orally available mIDH1 inhibitor.AGI-14100 is used for the treatment of primary human myeloid leukemia. |
| 靶点活性 | HT1080 (chondrosarcoma cell lines):1 nM, IDH1-R132H homodimer (mutation):6 nM |
| 体内活性 | AGI-14100 (50 mg/kg; oral; single; female nude BALB/c mice) inhibition robust tumor 2-HG was achieved 12 hours post-dose demonstrating desirable in vivo results.[1] |
| 别名 | AGI 14100 |
| 分子量 | 599.96 |
| 分子式 | C29H22ClF4N5O3 |
| CAS No. | 1448346-43-7 |
| Smiles | N([C@H](C(NC1CC(F)(F)C1)=O)C2=C(Cl)C=CC=C2)(C(=O)[C@H]3N(C(=O)CC3)C4=CC(C#N)=CC=N4)C5=CC(F)=CC(F)=C5 |
| 密度 | 1.51 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 50 mg/mL (83.34 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容